Circulating tumor cells in breast cancer--current status and perspectives.

摘要: The phenomenon of tumor cell dissemination through the blood stream has been known since 19th century. Circulating cells (CTCs) may be detected in peripheral patients with breast cancer and serve as a surrogate marker for minimal residual disease. Prognostic relevance CTCs already demonstrated early metastatic commercially available detection systems are currently employed various clinical trials. Since is an easily accessible compartment, serial reevaluation possible contribute to better therapy monitoring. Another potential lies characterization cells. Expression profiles differ between primary tumor, which result different responses treatment. Assessment molecular features important step optimization adjuvant systemic therapy.